Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why PFE stock is a Buy.

The antibody has shown promising results in preclinical studies, demonstrating 'superior' anti-tumour activity.

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary ...

Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...